Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical pharmacokinetics during continuous haemofiltration

F Bressolle1, J M Kinowski, J E de la Coussaye

  • 1Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Montpellier, France.

Clinical Pharmacokinetics
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the costs of disposable and reusable supplies wasted during surgeries.

International journal of surgery (London, England)·2018
Same author

Changes in the availability of bedside ultrasound practice in emergency rooms and prehospital settings in France.

Anaesthesia, critical care & pain medicine·2017
Same author

MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon): A Success Story of the European Innovation Partnership on Active and Healthy Ageing.

The Journal of frailty & aging·2016
Same author

Does the type of fluid affect rapidity of shock reversal in an anaesthetized-piglet model of near-fatal controlled haemorrhage? A randomized study.

British journal of anaesthesia·2013
Same author

Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.

Clinical drug investigation·2013
Same author

Stability of the ready-to-use solutions of eribulin for intravenous infusion.

Annales pharmaceutiques francaises·2012

Continuous haemofiltration (CHF) helps critically ill patients with acute renal failure by removing waste products. Understanding CHF

Area of Science:

  • Nephrology
  • Critical Care Medicine
  • Clinical Pharmacology

Background:

  • Continuous haemofiltration (CHF) is an extracorporeal technique for critically ill patients with acute renal failure.
  • Methods like continuous arteriovenous haemofiltration (CAVH) and continuous venovenous haemofiltration (CVVH) are used to remove fluid and waste.
  • Continuous arteriovenous or venovenous haemodiafiltration (CAVHD or CVVHD) combine haemofiltration with haemodialysis.

Purpose of the Study:

  • To summarize current knowledge on the clinical pharmacokinetic aspects of drug therapy during continuous haemofiltration.
  • To highlight the importance of understanding drug elimination during CHF for effective patient management.
  • To provide guidance on dosage adjustments for drugs used in patients undergoing CHF.

Main Methods:

Related Experiment Videos

  • Review of available literature on drug pharmacokinetics during continuous haemofiltration.
  • Analysis of factors influencing drug elimination, including ultrafiltration rate, protein binding, and membrane sieving coefficient.
  • Tabulation of commonly used drugs with updated pharmacokinetic and drug-monitoring information.

Main Results:

  • Drug elimination during CHF is influenced by ultrafiltration rate, protein binding, and membrane properties.
  • Dosage reduction may be necessary due to impaired renal function in patients undergoing CHF.
  • Dosage supplementation might be required if significant drug removal occurs during haemofiltration.

Conclusions:

  • Knowledge of CHF's impact on drug pharmacokinetics is crucial for safe and effective clinical management.
  • Accurate dosing strategies are essential to avoid adverse drug reactions and ensure therapeutic efficacy.
  • This summary provides essential information for healthcare professionals managing drug therapy in patients on CHF.